Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real ‐world evidence from the medicare population
ConclusionOver two ‐thirds of patients survived at least 2 years after starting their first observed therapy for CLL. Our findings highlight considerable susceptibility to AEs and unmet medical need in Medicare patients with CLL treated in routine practice. Medicare incurred substantial economic burden following in itiation of systemic therapy, and patients with greater numbers of AEs accounted disproportionately for the high overall cost of CLL management.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Ravi K. Goyal,
Saurabh P. Nagar,
Shaum M. Kabadi,
Hannah Le,
Keith L. Davis,
James A. Kaye Tags: ORIGINAL RESEARCH Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Databases & Libraries | Hypertension | Leukemia | Medicare | Rituxan | Study | Treanda